Artivion (AORT) AI Stock Analysis

• Market Cap: $2.02B
• Dividend Yield: N/A
• Average Volume (3M): 479.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.09
• Revenue Growth: 7.44%
• EPS Growth: -109.83%
• Country: US
• Employees: 1,600
• Sector: Healthcare
• Sector Strength: 50
• Industry: Medical - Devices
• EPS (TTM): 0.03
• Shares Outstanding: 47,183,660
• 10 Day Avg. Volume: 806,820
• 30 Day Avg. Volume: 479,165
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.80
• Enterprise Value/Revenue: 4.00
• Enterprise Value/Gross Profit: 6.26
• Enterprise Value/Ebitda: 40.73
• 1Y Price Target: $41.69
• Price Target Upside: -0.79% Downside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 55 Neutral
• Price Target: $45.00 ▲(7.09% Upside)

Artivion's overall score is driven by strong earnings call results and positive corporate events, but is weighed down by financial performance challenges and lack of technical analysis data.

Positive Factors

Financial Performance

The company beat revenue and adjusted EBITDA estimates, leading to an increase in its fiscal year guidance.

Growth Strategy

Artivion is raising its FY25 revenue and adjusted EBITDA guidance, indicating strong US growth driven by AMDS and On-X.

Product Launch

The company launched AMDS under HDE, which carries a strong initial stocking benefit, and most of the revenue thus far has been from stocking, according to the company.

Negative Factors

Cybersecurity Impact

A cybersecurity incident impacted Q4 revenue by $4.5M due to inventory constraints, causing revenue to fall below expectations.

Division Performance

Preservation Services was down 23% CC due to the previously disclosed cybersecurity incident.

Operational Challenges

Q1 is expected to continue feeling the impact of the cybersecurity incident, affecting revenue recognition.

Artivion Business Overview & Revenue Model

Company Description

Artivion, Inc. (AORT) is a medical technology company specializing in the development and commercialization of innovative surgical solutions for the treatment of cardiovascular diseases. The company primarily focuses on advanced bioengineered heart valves and minimally invasive surgical technologies, aiming to improve patient outcomes and reduce healthcare costs. Artivion's core products include its AORTIC® and PERIMOUNT® heart valve offerings, as well as its innovative surgical devices that are designed to assist in various cardiovascular procedures.

How the Company Makes Money

Artivion generates revenue primarily through the sale of its medical devices and surgical products. Key revenue streams include direct sales of its heart valves and associated surgical products to hospitals, surgical centers, and healthcare providers. Additionally, the company may derive income from licensing agreements, collaborations, and partnerships with other medical institutions and industry players. Significant factors contributing to its earnings include the growing demand for minimally invasive surgical solutions, advancements in cardiovascular treatments, and the company's ongoing investment in research and development to expand its product portfolio.

Artivion Financial Statement Overview

Summary

Artivion shows solid revenue growth but faces profitability challenges with negative net income and profit margins. The balance sheet is stable with limited leverage, and cash flow management needs improvement due to high capital expenditures.

Income Statement

Artivion's income statement shows a modest revenue growth trend over the years, with TTM (Trailing-Twelve-Months) revenue at $390 million, representing a steady increase from previous years. However, the company has been consistently generating net losses, with a TTM net income of -$21.4 million. Gross profit margin remains strong at 62.9% TTM, but the negative net profit margin of -5.5% and declining EBIT margin to 4.5% TTM indicate profitability challenges.

Balance Sheet

The balance sheet reflects a stable equity base with stockholders' equity at $294 million TTM, but a high debt-to-equity ratio of 0.03 in TTM suggests manageable leverage. The equity ratio is a solid 37.2%, indicating a balanced capital structure. Despite these strengths, the negative net income affects return on equity, which remains negative.

Cash Flow

Artivion's cash flow statement indicates a mixed performance. While operating cash flow is positive at $13.6 million TTM, free cash flow growth is weak due to high capital expenditures, resulting in a modest free cash flow of $2.1 million TTM. The operating cash flow to net income ratio is positive, showing some operational efficiency despite net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	405.04M	388.54M	354.00M	313.79M	298.84M	253.23M
Gross Profit	259.20M	248.78M	229.18M	202.52M	197.51M	167.78M
EBITDA	39.81M	50.97M	26.87M	25.30M	25.67M	27.68M
Net Income	-17.93M	-13.36M	-30.69M	-19.19M	-14.83M	-16.68M
Balance Sheet
Total Assets	838.39M	789.10M	792.40M	762.80M	793.05M	789.40M
Cash, Cash Equivalents and Short-Term Investments	53.48M	53.46M	58.94M	39.35M	55.01M	61.41M
Total Debt	8.79M	362.26M	358.34M	356.83M	362.04M	317.37M
Total Liabilities	418.49M	512.90M	510.62M	478.47M	492.32M	460.69M
Stockholders Equity	419.90M	276.20M	281.78M	284.33M	300.73M	328.71M
Cash Flow
Free Cash Flow	-11.08M	11.05M	11.39M	-15.87M	-15.68M	5.04M
Operating Cash Flow	1.98M	22.24M	18.82M	-5.15M	-2.58M	12.37M
Investing Cash Flow	-28.99M	-28.19M	-502.00K	-10.71M	5.66M	-73.13M
Financing Cash Flow	8.18M	2.20M	865.00K	-1.64M	-12.22M	93.61M

Artivion Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 42.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AORT, the sentiment is Positive. The current price of 42.02 is above the 20-day moving average (MA) of 36.06, above the 50-day MA of 32.71, and above the 200-day MA of 28.77, indicating a bullish trend. The MACD of 3.31 indicates Negative momentum. The RSI at 76.60 is Negative, neither overbought nor oversold. The STOCH value of 88.41 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AORT.

Artivion Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AXGN	70 Outperform	$712.73M	―	-4.48%	―	17.17%	72.68%
BVS	57 Neutral	$593.64M	―	-0.10%	―	5.08%	99.38%
AORT	55 Neutral	$2.02B	―	-5.01%	―	7.44%	-109.83%
OFIX	54 Neutral	$573.06M	―	-24.63%	―	4.84%	0.85%
KIDS	50 Neutral	$481.41M	―	-11.49%	―	26.08%	-63.67%
Sector *	46 Neutral	C$218.42M	-0.38	-24.34%	3.17%	19.38%	-2.35%
TNDM	44 Neutral	$732.45M	―	-111.91%	―	25.84%	-47.67%

Artivion Corporate Events

Artivion Appoints Lance A. Berry as COO

On August 6, 2025, Artivion, Inc. announced the appointment of Lance A. Berry as Chief Operating Officer, effective August 11, 2025. Berry, who will continue his roles as Chief Financial Officer and Treasurer, brings extensive experience from his previous positions at Wright Medical Group N.V. and Arthur Andersen. His compensation package includes a base salary, cash incentives, and equity grants. Additionally, Marshall S. Stanton, Senior Vice President, Clinical Research and Chief Medical Officer, announced his retirement effective March 31, 2026. Stanton will continue to offer strategic advice and transition services for up to a year post-retirement.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.

Artivion Completes Convertible Notes Exchange Agreement

On May 28, 2025, Artivion, Inc. announced the completion of transactions related to privately negotiated exchange agreements with holders of its 4.250% Convertible Senior Notes due 2025. These transactions involved exchanging approximately $99.54 million in principal amount of notes for 4,334,347 shares of common stock and a cash payment of $1.7 million for accrued interest. This move effectively retires the convertible notes, significantly reducing the company’s debt and enhancing its financial flexibility, as stated by CEO Pat Mackin.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.

Artivion Shareholders Approve Directors and Compensation

At the 2025 Annual Meeting of Stockholders on May 13, Artivion‘s shareholders elected all nominated directors and approved executive compensation packages. Additionally, they ratified Ernst & Young LLP as the independent auditor for 2025 and approved additional shares for the company’s equity incentive plan, indicating strong shareholder support for the company’s strategic direction.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.

Artivion Announces Convertible Notes Exchange Agreement

On May 14, 2025, Artivion, Inc. announced that it entered into privately negotiated exchange agreements with holders of its 4.250% Convertible Senior Notes due July 1, 2025. The agreements involve exchanging approximately $94.54 million in principal amount of these notes for shares of the company’s common stock, with the number of shares determined by the stock’s average trading price over a specified period. The transaction is expected to close around May 28, 2025, and will leave approximately $5.46 million of the notes outstanding. This strategic move is anticipated to impact Artivion’s financial structure and market positioning, potentially affecting stakeholders by altering the company’s debt and equity composition.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.